Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...

There was a meaningful reduction in the risk for non-small cell lung cancer (NSCLC) recurrence or death in post-surgical ...

Despite the activity observed with nivolumab and ipilimumab in this exploratory analysis ... 3 weeks [on day 1 or on days 1 and 8 of each 3-week cycle]; three cycles) as neoadjuvant treatment. Surgery ...

significantly outperformed nivolumab monotherapy in both event-free survival and metastasis-free survival. “Neoadjuvant therapy provides the added benefit of assessing histological or ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...

In addition to multiple treatment-arm phase I trials where this antibody is being combined with various chemotherapy regimens, nivolumab is also being explored in the neoadjuvant setting in ...

Initial findings from the phase II NURE-Combo trial, reported in the Journal of Clinical Oncology, showed the combination of neoadjuvant nivolumab (Opdivo) and nab-paclitaxel (Abraxane ...

Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC ...